TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37091549

Group type: EXPERIMENTAL
Intervention: Home pregnancy test use
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Barriers to home pregnancy test use
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Community knowledge improvement
Number of subjects: 48
Study: 37091963

Group type: EXPERIMENTAL
Intervention: BNT162b2
Number of subjects: 60

Group type: COMPARATOR
Intervention: JNJ-78436735
Number of subjects: 60
Study: 37092011

Group type: EXPERIMENTAL
Intervention: At-home transcranial Direct Current Stimulation (tDCS) for 20 minutes, 5 days/week for 8 weeks.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham tDCS procedure providing no effective stimulation.
Number of subjects: 100
Study: 37092287

Group type: EXPERIMENTAL
Intervention: V-LAP monitoring system
Number of subjects: 30
Study: 37092730

Group type: EXPERIMENTAL
Intervention: Czech version of the LSITA-SF12 questionnaire
Number of subjects: 1113
Study: 37092829

Group type: EXPERIMENTAL
Intervention: Diaphragm thickening fraction (DTF)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Esophageal pressure swing (∆P es)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Number of subjects: 13
Study: 37092958

Group type: EXPERIMENTAL
Intervention: Potassium Titanyl Phosphate Laser
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium Hypochlorite
Number of subjects: 0
Study: 37093057

Group type: EXPERIMENTAL
Intervention: Capsulized fecal microbiota transplantation (FMT)
Number of subjects: 22
Study: 37093069

Group type: EXPERIMENTAL
Intervention: Simultaneous resection (SIMR) with major liver resection
Number of subjects: 766

Group type: COMPARATOR
Intervention: Simultaneous resection (SIMR) with minor liver resection
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: American Society of Anesthesiologists grades ≥3
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Major liver resection
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Left-sided colectomy
Number of subjects: 766
Study: 37093072

Group type: EXPERIMENTAL
Intervention: IMMUNOREACT 1 cohort (therapy naive)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: IMMUNOREACT 2 cohort (patients who had neoadjuvant therapy)
Number of subjects: 442

Group type: COMPARATOR
Intervention: TGCA series
Number of subjects: 442

Group type: COMPARATOR
Intervention: General findings
Number of subjects: 442
Study: 37093074

Group type: EXPERIMENTAL
Intervention: Circulating fibrocyte percentage (CFP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Neutrophil-lymphocyte ratio (NLR)
Number of subjects: 80
Study: 37093160

Group type: EXPERIMENTAL
Intervention: Oral Cannabidiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37093196

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37093248

Group type: EXPERIMENTAL
Intervention: Frequency of cannabis use
Number of subjects: 0
Study: 37093298

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37093350

Group type: EXPERIMENTAL
Intervention: Anti-CD70 VHH construct with C-direct-tag
Number of subjects: 0
Study: 37093466

Group type: EXPERIMENTAL
Intervention: SYHA1402 25 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SYHA1402 50 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SYHA1402 100 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SYHA1402 200 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SYHA1402 400 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SYHA1402 800 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SYHA1402 (all doses)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SYHA1402 (25-100 mg)
Number of subjects: 54
Study: 37093512

Group type: EXPERIMENTAL
Intervention: Dutch adults with OSA
Number of subjects: 28

Group type: COMPARATOR
Intervention: Chinese adults with OSA
Number of subjects: 28
Study: 37093572

Group type: EXPERIMENTAL
Intervention: Transvaginal pudendal nerve block (9 mL 0.25% bupivacaine and 1 mL 40 mg/mL triamcinolone)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sham injection (10 mL normal saline)
Number of subjects: 71
Study: 37093628

Group type: EXPERIMENTAL
Intervention: The Secret Trail of Moon (TSTM)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Therapeutic Chess (TC)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 104
Study: 37093634

Group type: EXPERIMENTAL
Intervention: Perioperative digital app via the LeoMed telecare platform for 1 month
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard of care without personalized digital support
Number of subjects: 1000
Study: 37093641

Group type: EXPERIMENTAL
Intervention: Brief barrier reduction intervention (BRI) with tailored message based on self-reported barriers (n=388)
Number of subjects: 776

Group type: COMPARATOR
Intervention: Care as usual (general advisory text) (n=388)
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Brief barrier reduction intervention (BRI)
Number of subjects: 776
Study: 37093712

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg subcutaneously
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 35
Study: 37093833

Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Hormone monotherapy
Number of subjects: 300
Study: 37093892

Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies (nAbs) from plasma samples of SFV-infected individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies (nAbs)
Number of subjects: 0
Study: 37094184

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37094330

Group type: EXPERIMENTAL
Intervention: Secondary TMA
Number of subjects: 336

Group type: COMPARATOR
Intervention: Atypical HUS
Number of subjects: 336

Group type: COMPARATOR
Intervention: TTP
Number of subjects: 336

Group type: COMPARATOR
Intervention: Shigatoxin-associated HUS
Number of subjects: 336
Study: 37094349

Group type: EXPERIMENTAL
Intervention: Cash transfer of 1000 rupees (U.S. $12)
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) and Cash transfer together
Number of subjects: 1120
Study: 37094336

Group type: EXPERIMENTAL
Intervention: Hypotension-avoidance strategy
Number of subjects: 7490

Group type: COMPARATOR
Intervention: Hypertension-avoidance strategy
Number of subjects: 7490
Study: 37094596

Group type: EXPERIMENTAL
Intervention: Chemotherapy with rituximab
Number of subjects: 421
Study: 37094668

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month dual antiplatelet therapy
Number of subjects: 13136

Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin after 3-month dual antiplatelet therapy
Number of subjects: 13136
Study: 37094692

Group type: EXPERIMENTAL
Intervention: EUS-guided gastroenterostomy (EUS-GE); technical success 97.1%, clinical success 97.1%, adverse events in 12.9% of patients, symptom recurrence 7.6% after median follow-up of 105 days.
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: EUS-guided gastroenterostomy (EUS-GE)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Enteral stenting (ES)
Number of subjects: 104
Study: 37094777

Group type: EXPERIMENTAL
Intervention: Self-declared ERAS centres
Number of subjects: 743

Group type: COMPARATOR
Intervention: Non-ERAS centres
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Overall adherence to ERAS pathway
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Higher ERAS adherence quartiles (Q1, > 60%)
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Lower ERAS adherence quartiles (Q4, ≤ 45%)
Number of subjects: 743
Study: 37094892

Group type: EXPERIMENTAL
Intervention: Manual therapy combined with therapeutic exercise for 10 weeks (two visits per week)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Routine physical therapy
Number of subjects: 52
Study: 37094895

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 14
Study: 37094943

Group type: EXPERIMENTAL
Intervention: 0.6% Lugol's solution
Number of subjects: 242

Group type: COMPARATOR
Intervention: 1.2% Lugol's solution
Number of subjects: 242
Study: 37094945

Group type: EXPERIMENTAL
Intervention: Women with T2DM
Number of subjects: 1837
Study: 37094968

Group type: EXPERIMENTAL
Intervention: Patient blood management program (high-dose iron supplements before and after surgery)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 334
Study: 37094988

Group type: EXPERIMENTAL
Intervention: Intravenous enadenotucirev plus nivolumab
Number of subjects: 51
Study: 37094998

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Interferon β1-a
Number of subjects: 8
Study: 37094997

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 33,000 IU
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 37095120

Group type: EXPERIMENTAL
Intervention: Single-target CD19 CAR T-cell therapy
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Dual-target tandem CD19/CD22 CAR T-cell therapy
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Dual-target sequential CD19/CD22 CAR T-cell therapy
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: High-risk factors in tandem CD19/CD22 group
Number of subjects: 219
Study: 37095250

Group type: EXPERIMENTAL
Intervention: Tau-targeting antisense oligonucleotide (MAPT), dosage and duration not specified
Number of subjects: 0
Study: 37095285

Group type: EXPERIMENTAL
Intervention: Incentivized peer referral (IPR) with a $5 incentive for each peer enrolled.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incentivized peer referral (IPR)
Number of subjects: 0
Study: 37095298

Group type: EXPERIMENTAL
Intervention: Bivalirudin use during operation (BUDO, 0.75 mg/kg bolus plus 1.75 mg/kg/h)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Bivalirudin use during and after operation for 4 h (BUDAO, 0.75 mg/kg bolus plus 1.75 mg/kg/h)
Number of subjects: 330
Study: 37095342

Group type: EXPERIMENTAL
Intervention: Molidustat
Number of subjects: 2

Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 2
Study: 37095378

Group type: EXPERIMENTAL
Intervention: Adenoviral and inactivated-virus vaccines (heterologous combinations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mRNA vaccine as the second dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated-virus vaccine (priming)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Boosting with inactivated-virus vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different vaccine combinations
Number of subjects: 0
Study: 37095433

Group type: EXPERIMENTAL
Intervention: VR meditation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: VR game
Number of subjects: 24
Study: 37095473

Group type: EXPERIMENTAL
Intervention: Vibegron
Number of subjects: 0
Study: 37095488

Group type: EXPERIMENTAL
Intervention: Ultrasonic/curette subgingival instrumentation and erythritol air-polishing (test)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ultrasonic/curette instrumentation only (control)
Number of subjects: 43
Study: 37095547

Group type: EXPERIMENTAL
Intervention: Evaluation by female investigator
Number of subjects: 245

Group type: COMPARATOR
Intervention: Evaluation by male investigator
Number of subjects: 245
Study: 37095557

Group type: COMPARATOR
Intervention: BI 685,509 (moderate or high dose) for 24 weeks in patients with CSPH due to alcohol-related liver disease
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: BI 685,509 (high dose) alone for 8 weeks in patients with hepatitis B or C virus infection or NASH
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: BI 685,509 (high dose) in combination with 10 mg empagliflozin for 8 weeks in patients with NASH and type 2 diabetes mellitus
Number of subjects: 185
Study: 37095561

Group type: EXPERIMENTAL
Intervention: Integrated HCV treatment
Number of subjects: 276

Group type: COMPARATOR
Intervention: Standard HCV treatment
Number of subjects: 276
Study: 37095571

Group type: EXPERIMENTAL
Intervention: Culturally adapted motivational interviewing with cognitive behavior therapy and mindfulness-based relapse prevention, delivered weekly over a period of 12 weeks.
Number of subjects: 260
Study: 37095637

Group type: EXPERIMENTAL
Intervention: 9 IU·kg -1 ·bw -1 epoetin β (rHuEPO)
Number of subjects: 48

Group type: COMPARATOR
Intervention: saline (0.9% NaCl)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ABP with RET% and ABPS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ABP with IRF and IR/RBC
Number of subjects: 48
Study: 37095689

Group type: EXPERIMENTAL
Intervention: Third-dose triple combination therapy (ALC group; amlodipine 1.67 mg + losartan potassium 16.67 mg + chlorthalidone 4.17 mg)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Third-dose dual combination therapy (AL group; amlodipine 1.67 mg + losartan potassium 16.67 mg)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Third-dose dual combination therapy (LC group; losartan potassium 16.67 mg + chlorthalidone 4.17 mg)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Third-dose dual combination therapy (AC group; amlodipine 1.67 mg + chlorthalidone 4.17 mg)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Third-dose triple combination therapy (ALC group)
Number of subjects: 245
Study: 37095769

Group type: EXPERIMENTAL
Intervention: Single measurement of Lp(a) levels in the peri-infarction setting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lp(a) levels six months after the initial event
Number of subjects: 0
Study: 37096015

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 724

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study: 37096093

Group type: EXPERIMENTAL
Intervention: Transbronchial injection of iron sucrose, median injection 90 mL (range, 70-120 mL)
Number of subjects: 20
Study: 37096186

Group type: EXPERIMENTAL
Intervention: 30 g/day of raw walnut kernels for 6 months
Number of subjects: 771

Group type: COMPARATOR
Intervention: Control group (no walnut consumption)
Number of subjects: 771
Study: 37096188

Group type: EXPERIMENTAL
Intervention: Gumarontinib monotherapy
Number of subjects: 84
Study: 37096236

Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 0
Study: 37096396

Group type: EXPERIMENTAL
Intervention: Vadadustat
Number of subjects: 309

Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 309
Study: 37096402

Group type: EXPERIMENTAL
Intervention: Total postoperative opioid dose (TPOD)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Intravenous sufentanil dose on postoperative day 1 (POD1)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with basal infusion
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group (no PPOI)
Number of subjects: 267
Study: 37096495

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (placebo, autologous FMT, no intervention, or antibiotics)
Number of subjects: 320
Study: 37096777

Group type: EXPERIMENTAL
Intervention: Prototype #10 single-renal scallop stent-graft
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Prototype #15 single-renal scallop stent-graft
Number of subjects: 547

Group type: COMPARATOR
Intervention: Standard stent-graft (control group)
Number of subjects: 547
Study: 37096802

Group type: COMPARATOR
Intervention: Standard interferon
Number of subjects: 997

Group type: COMPARATOR
Intervention: PEG interferon
Number of subjects: 997

Group type: COMPARATOR
Intervention: High-dose PEG interferon
Number of subjects: 997

Group type: COMPARATOR
Intervention: Standard interferon plus ribavirin
Number of subjects: 997

Group type: COMPARATOR
Intervention: PEG interferon plus ribavirin
Number of subjects: 997

Group type: COMPARATOR
Intervention: Grazoprevir plus elbasvir
Number of subjects: 997

Group type: COMPARATOR
Intervention: Telaprevir plus ribavirin plus PEG interferon
Number of subjects: 997
Study: 37096956

Group type: EXPERIMENTAL
Intervention: Varenicline solution nasal spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37097109

Group type: EXPERIMENTAL
Intervention: Wearable alcohol biosensor
Number of subjects: 27
Study: 37097283

Group type: EXPERIMENTAL
Intervention: TECNIS Synergy intraocular lens (IOL), model ZFR00V
Number of subjects: 272

Group type: COMPARATOR
Intervention: TECNIS IOL, model ZCB00
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: TECNIS Synergy ZFR00V
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: TECNIS Synergy ZFR00V and TECNIS IOL ZCB00
Number of subjects: 272
Study: 37097330

Group type: EXPERIMENTAL
Intervention: Minimally invasive right hemicolectomy (MIRH)
Number of subjects: 1095
Study: 37097604

Group type: EXPERIMENTAL
Intervention: Nadroparin 5.900 IU subcutaneously twice daily in mechanically ventilated patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: Nadroparin 5.900 IU subcutaneously once daily in patients supplemented with conventional oxygen
Number of subjects: 43
Study: 37097715

Group type: EXPERIMENTAL
Intervention: Pembrolizumab administered three-times weekly for 1 year or until progression, starting 30-45 days after TACE.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Radiological responses evaluated every four cycles.
Number of subjects: 32
Study: 37097726

Group type: EXPERIMENTAL
Intervention: Aim2Be with a live coach for 6 months
Number of subjects: 214

Group type: COMPARATOR
Intervention: Aim2Be with no live coach (waitlist control)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Aim2Be with live coaching
Number of subjects: 214

Group type: COMPARATOR
Intervention: Aim2Be with no coaching (waitlist control)
Number of subjects: 214
Study: 37097739

Group type: EXPERIMENTAL
Intervention: W-iCBT
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 182

Group type: COMPARATOR
Intervention: WLC
Number of subjects: 182
Study: 37097894

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 851

Group type: COMPARATOR
Intervention: Adalimumab 40 mg
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Both secukinumab and adalimumab
Number of subjects: 851
Study: 37097898

Group type: EXPERIMENTAL
Intervention: SND score based on clinical and radiological factors (age >60 years, prehospital or admission arterial hypotension, frontal contusion, Marshall CT score of 6)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Age >60 years
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Brain frontal contusion
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Prehospital or admission arterial hypotension
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Marshall CT score of 6
Number of subjects: 142
Study: 37097924

Group type: EXPERIMENTAL
Intervention: Carbohydrate intake measured using 24-hour dietary recalls (SPRING) or Food Frequency Questionnaire (BABI)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Breastfeeding status added to the model
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Glycemic index
Number of subjects: 281
Study: 37097986

Group type: EXPERIMENTAL
Intervention: Lung recruitment assessed by electrical impedance tomography
Number of subjects: 0
Study: 37098004

Group type: EXPERIMENTAL
Intervention: Branched chain amino acids (BCAA) intake measured in grams (g) per 1000 kilocalories (kcal) of energy intake (range 3.0-34.8 g/1000 kcal)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: BCAA modeled as a ratio of BCAA to total protein intake
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Absolute BCAA intake
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: BCAA intake
Number of subjects: 656
Study: 37098131

Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg for 4 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 37098173

Group type: EXPERIMENTAL
Intervention: Single Lavender Essential Oil (SLEO)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Complex Lavender Essential Oil (CLEO)
Number of subjects: 53
Study: 37098232

Group type: EXPERIMENTAL
Intervention: Sotorasib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37098399

Group type: EXPERIMENTAL
Intervention: Franseen needle
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 3-prong asymmetric-tip needle
Number of subjects: 114
Study: 37098409

Group type: EXPERIMENTAL
Intervention: 1 mg prucalopride for 6 days
Number of subjects: 50
Study: 37098453

Group type: EXPERIMENTAL
Intervention: Clindamycin gel
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 307
Study: 37098468

Group type: EXPERIMENTAL
Intervention: Revised Mentor Mother services (INT)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Both arms (INT and SC)
Number of subjects: 309
Study: 37098469

Group type: EXPERIMENTAL
Intervention: Patients with NDPH
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 29
Study: 37098492

Group type: EXPERIMENTAL
Intervention: Postoperative hypothermia
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Preoperative hypothermia
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Intraoperative hypothermia
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: ASA physical status III-IV
Number of subjects: 742
Study: 37098494

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) 45 Gy in 5 fractions given every 3-4 days
Number of subjects: 0
Study: 37098506

Group type: EXPERIMENTAL
Intervention: Standard treatment approaches for problem gambling
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Screening and assessment procedure for problem gambling
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Systematic screening for problem gambling at admission and every 6 months thereafter
Number of subjects: 800
Study: 37098529

Group type: EXPERIMENTAL
Intervention: Olipudase alfa enzyme replacement therapy
Number of subjects: 5